1 |
Yoon M. PPAR in Obesity: Sex Difference and Estrogen Involvement. PPAR Res. 2010. 2010.
|
2 |
Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats. Diabetes Obes Metab. 2009. 11: 632-636.
DOI
ScienceOn
|
3 |
Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F. Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett. 2001. 491: 154-158.
DOI
ScienceOn
|
4 |
Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci. 2004. 61: 393-416.
DOI
ScienceOn
|
5 |
Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. Diabetes. 2002. 51: 901-909.
DOI
ScienceOn
|
6 |
Mystkowski P, Schwartz MW. Gonadal steroids and energy homeostasis in the leptin era. Nutrition. 2000. 16: 937-946.
DOI
ScienceOn
|
7 |
Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology. 2008. 54: 226-234.
DOI
ScienceOn
|
8 |
Simoneau JA, Lortie G, Boulay MR, Thibault MC, Theriault G, Bouchard C. Skeletal muscle histochemical and biochemical characteristics in sedentary male and female subjects. Can J Physiol Pharmacol. 1985. 63: 30-35.
DOI
ScienceOn
|
9 |
Staels B. PPAR agonists and the metabolic syndrome. Therapie. 2007. 62: 319-326.
DOI
ScienceOn
|
10 |
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998. 98: 2088-2093.
DOI
ScienceOn
|
11 |
Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol. 2000. 20: 1868-1876.
DOI
ScienceOn
|
12 |
Wade GN. Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol. 1975. 88: 183-193.
DOI
ScienceOn
|
13 |
Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes. 2001. 50: 411-417.
DOI
ScienceOn
|
14 |
Yoon M, Jeong S, Nicol CJ, Lee H, Han M, Kim JJ, Seo YJ, Ryu C, Oh GT. Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism. Exp Mol Med. 2002. 34: 481-488.
DOI
ScienceOn
|
15 |
Yoon M, Jeong S, Lee H, Han M, Kang JH, Kim EY, Kim M, Oh GT. Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Biochem Biophys Res Commun. 2003. 302: 29-34.
DOI
ScienceOn
|
16 |
Yoon M. The role of PPAR in lipid metabolism and obesity: Focusing on the effects of estrogen on PPAR actions. Pharmacological Research. 2009. 60: 151-159.
DOI
ScienceOn
|
17 |
Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998. 273: 29577-29585.
DOI
|
18 |
Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999. 20: 649-688.
|
19 |
Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. J Clin Endocrinol Metab. 2005. 90: 1791-1797.
DOI
|
20 |
Geary N, Asarian L. Estradiol increases glucagon's satiating potency in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol. 2001. 281: R1290-R1294.
DOI
|
21 |
Green HJ, Fraser IG, Ranney DA. Male and female differences in enzyme activities of energy metabolism in vastus lateralis muscle. J Neurol Sci. 1984. 65: 323-331.
DOI
ScienceOn
|
22 |
Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B. Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000. 275: 16638-16642.
DOI
ScienceOn
|
23 |
Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004. 53: S43-S50.
DOI
ScienceOn
|
24 |
Janssen I, Heymsfield SB, Baumgartner RN, Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000. 89: 465-471.
DOI
|
25 |
Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus. Curr Diabetes Rev. 2007. 3: 33-39.
DOI
ScienceOn
|
26 |
Jeong S, Choi WC, Yoon M. Effects of fenofibrate on adipogenesis in female C57BK/6J mice. J Exp Biomed Sci. 2005. 11: 1-8.
|
27 |
Jeong S, Choi HK, Yoon M. Morphological changes in adipose and liver tissues by 17-estradiol in female ovariectomized C57BL/6 mice. J Exp Biomed Sci. 2007. 13: 99-104.
|
28 |
Jeong S, Kim M, Han M, Lee H, Ahn J, Kim M, Song YH, Shin C, Nam KH, Kim TW, Oh GT, Yoon M. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Metabolism. 2004a. 53: 607-613.
DOI
ScienceOn
|
29 |
Jeong S, Han M, Lee H, Kim M, Kim J, Nicol CJ, Kim BH, Choi JH, Nam KH, Oh GT, Yoon M. Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice. Metabolism. 2004b. 53: 1284-1289.
DOI
ScienceOn
|
30 |
Jeong S, Yoon M. Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen. Obesity (Silver Spring). 2007. 15: 1430-1440.
DOI
ScienceOn
|
31 |
Komi PV, Karlsson J. Skeletal muscle fibre types, enzyme activities and physical performance in young males and females. Acta Physiol Scand. 1978. 103: 210-218.
DOI
ScienceOn
|
32 |
Arany Z. PGC-1 coactivators and skeletal muscle adaptations in health and disease. Curr Opin Genet Dev. 2008. 18: 426-434.
DOI
ScienceOn
|
33 |
Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med. 2000. 10: 238-245.
DOI
ScienceOn
|
34 |
Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008. 28: 39-46.
DOI
ScienceOn
|
35 |
Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005. 26: 244-251.
DOI
ScienceOn
|
36 |
Brandt JM, Djouadi F, Kelly DP. Fatty acids activate transcription of the muscle carnitine palmitoyltransferase I gene in cardiac myocytes via the peroxisome proliferator-activated receptor alpha. J Biol Chem. 1998. 273: 23786-23792.
DOI
ScienceOn
|
37 |
Chai JK, Blaha V, Meguid MM, Laviano A, Yang ZJ, Varma M. Use of orchiectomy and testosterone replacement to explore meal number-to-meal size relationship in male rats. Am J Physiol. 1999. 276: R1366-R1373.
|
38 |
Chaput E, Saladin R, Silvestre M, Edgar AD. Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000. 271: 445-450.
DOI
ScienceOn
|
39 |
Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, Reitman ML. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. J Biol Chem. 2002. 277: 24484-24489.
DOI
ScienceOn
|
40 |
Zhang F, Lavan B, Gregoire FM. Peroxisome proliferator-activated receptors as attractive antiobesity targets. Drug News Perspect. 2004. 17: 661-669.
DOI
ScienceOn
|